Abu Dhabi Stem Cells Center (ADSCC) and Burjeel Holdings have announced a partnership to expand bone marrow transplant and cellular therapy services at Burjeel Medical City (BMC).
The collaboration aims to improve access to advanced care for patients with blood cancer, genetic diseases, and autoimmune conditions.
Expanding bone marrow care
ADSCC will extend its Abu Dhabi Bone Marrow Transplant Programme (AD-BMT) to BMC. The programme is accredited by the Department of Health – Abu Dhabi and recognised by the Foundation for the Accreditation of Cellular Therapy.
“Our vision is to create a comprehensive, world-class bone marrow transplant programme that delivers the highest standards of care while also pushing the boundaries of innovation. This partnership is a major step forward in achieving that goal. Together, we are setting new benchmarks in patient outcomes and medical excellence,” John Sunil, CEO of Burjeel Holdings said.
Since 2020, ADSCC has performed over 120 bone marrow transplants and 15 CAR-T Cell Therapies.
The centre conducted clinical trials, including one for Extracorporeal Photopheresis in Multiple Sclerosis patients.
Burjeel Cancer Institute (BCI), based at BMC, has completed 142 pediatric and adult bone marrow transplants, including the UAE’s first pediatric BMT in 2022.
Prof. Yendry Ventura, Chief Executive Officer of Abu Dhabi Stem Cells Center, and Adjunct Professor at United Arab Emirates University added: “Guided by the UAE’s visionary leadership, ADSCC was the first to introduce bone marrow transplantation and cellular therapy in the UAE in 2020, providing advanced critical care regionally and running high-level research and clinical trials in the field. As demand grew, ADSCC expanded to offer CAR-T Cell Therapy, offering further cutting-edge treatment options to patients.
“Today, we are pleased to witness the extension of these critical services at BMC in collaboration with Burjeel Holdings. As one of the few centres in the region providing this level of advanced care, we aim to reduce the need for patients to travel abroad for advanced care and to set new standards in cellular therapy with strong clinical outcomes.”
The collaboration is expected to enhance the bone marrow transplant landscape in the UAE and the wider region.
Follow us on
